BC Week In Review | Jan 13, 2017
Clinical News

Oral Debio 1450: Ph II data

Top-line data from 284 evaluable patients with ABSSSIs due to Staphylococcus , including methicillin-sensitive or methicillin-resistant S. aureus (MSSA or MRSA), in the microbiological intent-to-treat (mITT) population of a double-blind, U.S. Phase II trial showed that...
BC Week In Review | Jan 13, 2017
Clinical News

IV Debio 1450: Ph II data

Top-line data from 284 evaluable patients with ABSSSIs due to Staphylococcus, including methicillin-sensitive or methicillin-resistant S. aureus (MSSA or MRSA), in the microbiological intent-to-treat (mITT) population of a double-blind, U.S. Phase II trial showed that...
BC Extra | Jan 10, 2017
Clinical News

Debiopharm antibiotic passes Phase II ABSSSI test

Debiopharm Group (Lausanne, Switzerland) said antibiotic candidate Debio 1450 met the primary endpoint of non-inferiority to vancomycin plus linezolid across all tested Staphylococcus species in a Phase II trial to treat acute bacterial skin and...
BC Week In Review | Jun 1, 2015
Clinical News

Debio 1450: Phase II started

Debiopharm began a double-blind, placebo-controlled, U.S. Phase II trial to compare 2 doses of IV Debio 1450 given 12 hours apart followed by twice-daily oral Debio 1450 vs. 2 doses of IV vancomycin given 12...
BC Week In Review | Jun 1, 2015
Clinical News

Debio 1450: Phase II started

Debiopharm began a double-blind, placebo-controlled, U.S. Phase II trial to compare 2 doses of IV Debio 1450 given 12 hours apart followed by twice-daily oral Debio 1450 vs. 2 doses of IV vancomycin given 12...
BC Week In Review | Sep 22, 2014
Clinical News

Debio 1450 regulatory update

Debiopharm said FDA granted Qualified Infectious Disease Product (QIDP) designation to Debio 1450 to treat acute bacterial skin and skin structure infections (ABSSSI). The small molecule prodrug inhibitor of the bacterial fabI enoyl-(acyl carrier protein)...
BC Week In Review | Jun 23, 2014
Clinical News

oral Debio 1450: Phase I started

Debiopharm began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate single ascending-doses of oral Debio 1450 in up to 48 healthy subjects. An IV formulation of the product is in Phase I testing. Debiopharm...
BC Week In Review | Feb 17, 2014
Company News

Affinium, Debiopharm deal

Debiopharm acquired all of the drug development assets of antibiotics company Affinium, which will now wind down operations. Debiopharm declined to disclose financial details. Affinium's technology is used for structure-guided discovery of fatty acid biosynthesis...
BC Extra | Feb 12, 2014
Company News

Debiopharm acquires Affinium's antibiotic assets

Debiopharm Group (Lausanne, Switzerland) acquired all of the assets of antibiotics company Affinium Pharmaceuticals Ltd. (Austin, Texas), which will now wind down operations. Financial terms of the deal were not disclosed. The assets include Affinium's...
BC Week In Review | Sep 16, 2013
Clinical News

AFN-1720: Phase I started

Affinium began a placebo-controlled Phase I trial to evaluate single ascending-doses of IV AFN-1720 in healthy volunteers. The compound is a prodrug of Affinium's AFN-1252 , which is in Phase II testing to treat acute bacterial...
Items per page:
1 - 10 of 10